Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panax notoginseng, commonly known as Sanqi or Tienchi ginseng, is a perennial herb in the Araliaceae family native to East Asia. It is a cornerstone of traditional Chinese medicine, primarily utilized for its hemostatic, anti-thrombotic, and anti-inflammatory properties. The therapeutic effects are largely attributed to its high concentration of dammarane-type triterpene saponins, known as notoginsenosides. In modern clinical research, Panax notoginseng is being investigated for its potential to mitigate aspirin resistance and anti-platelet drug resistance in patients at risk for secondary stroke or cerebral infarction. Its mechanism of action involves the modulation of the TLR4/MyD88/NF-κB inflammatory signaling pathway and the inhibition of platelet activation and aggregation. Additionally, it is being explored in combination regimens for the treatment of colorectal cancer and the neuroprotection of patients in the recovery phase of ischemic stroke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on panax notoginseng.